Live Price Coverage: Could Versartis Inc See a Reversal After This Very Strong Session?

Live Price Coverage: Could Versartis Inc See a Reversal After This Very Strong Session?

The stock of Versartis Inc (NASDAQ:VSAR) is a huge mover today! About 228,594 shares traded hands or 30.77% up from the average. Versartis Inc (NASDAQ:VSAR) has risen 67.59% since March 1, 2016 and is uptrending. It has outperformed by 58.34% the S&P500.
The move comes after 9 months positive chart setup for the $419.80M company. It was reported on Oct, 4 by Barchart.com. We have $24.46 PT which if reached, will make NASDAQ:VSAR worth $415.60M more.

Analysts await Versartis Inc (NASDAQ:VSAR) to report earnings on November, 3. They expect $-0.84 EPS, down 21.74% or $0.15 from last year’s $-0.69 per share. After $-0.75 actual EPS reported by Versartis Inc for the previous quarter, Wall Street now forecasts 12.00% negative EPS growth.

Versartis Inc (NASDAQ:VSAR) Ratings Coverage

Out of 5 analysts covering Versartis Inc (NASDAQ:VSAR), 3 rate it a “Buy”, 1 “Sell”, while 1 “Hold”. This means 60% are positive. Versartis Inc has been the topic of 7 analyst reports since August 13, 2015 according to StockzIntelligence Inc. The company was downgraded on Thursday, December 17 by Credit Suisse. As per Thursday, April 7, the company rating was initiated by Northland Capital. The rating was initiated by Morgan Stanley with “Equal Weight” on Thursday, August 13. The rating was maintained by Canaccord Genuity on Monday, September 21 with “Buy”. The rating was maintained by Citigroup with “Buy” on Thursday, August 11. Credit Suisse initiated the shares of VSAR in a report on Thursday, August 20 with “Neutral” rating.

According to Zacks Investment Research, “Versartis, Inc. operates as a biotechnology company. It develops therapeutic proteins for the treatment of metabolic diseases and endocrine disorders. The Company is developing VRS-317, a long-acting recombinant human growth hormone, which is in Phase 2a clinical trials for the treatment of growth hormone deficiency. Versartis, Inc. is headquartered in Redwood City, California.”

Insitutional Activity: The institutional sentiment increased to 3 in Q2 2016. Its up 1.93, from 1.07 in 2016Q1. The ratio increased, as 5 funds sold all Versartis Inc shares owned while 8 reduced positions. 5 funds bought stakes while 34 increased positions. They now own 20.36 million shares or 0.09% more from 20.34 million shares in 2016Q1.
Parametric Assocs Lc reported 47,728 shares or 0% of all its holdings. Bnp Paribas Arbitrage reported 1,082 shares or 0% of all its holdings. New York State Common Retirement Fund holds 0% of its portfolio in Versartis Inc (NASDAQ:VSAR) for 20,500 shares. State Bank Of America De has invested 0% of its portfolio in Versartis Inc (NASDAQ:VSAR). California State Teachers Retirement System owns 57,295 shares or 0% of their US portfolio. Fmr Lc holds 3.61 million shares or 0.01% of its portfolio. Moreover, Oxford Asset has 0.04% invested in Versartis Inc (NASDAQ:VSAR) for 80,989 shares. Nationwide Fund Advsrs owns 56,765 shares or 0% of their US portfolio. Moreover, Alliancebernstein Limited Partnership has 0% invested in Versartis Inc (NASDAQ:VSAR) for 12,800 shares. Amer Int Group Inc has 0% invested in the company for 15,729 shares. Barclays Public Limited Company last reported 537 shares in the company. Ubs Asset Americas reported 12,500 shares or 0% of all its holdings. Moreover, National Bank Of New York Mellon Corporation has 0% invested in Versartis Inc (NASDAQ:VSAR) for 106,565 shares. Rhumbline Advisers has 0% invested in the company for 27,781 shares. Morgan Stanley holds 0% or 5,934 shares in its portfolio.

Insider Transactions: Since April 21, 2016, the stock had 0 insider buys, and 6 sales for $137,745 net activity. Brumm Joshua T sold 1,448 shares worth $15,392. $7,707 worth of Versartis Inc (NASDAQ:VSAR) shares were sold by Westberg Paul. 5,442 shares were sold by Shepard Jay, worth $70,093 on Monday, August 22. Varian John also sold $20,755 worth of Versartis Inc (NASDAQ:VSAR) shares.

More recent Versartis Inc (NASDAQ:VSAR) news were published by: Quotes.Wsj.com which released: “Versartis Inc. VSAR (US: Nasdaq)” on March 21, 2014. Also Marketwatch.com published the news titled: “/quotes/zigman/3870025/realtime” on March 21, 2014. Benzinga.com‘s news article titled: “Versartis Reports Data from Up to 30 Mos. of Somavaratan Treatment for …” with publication date: September 12, 2016 was also an interesting one.

VSAR Company Profile

Versartis, Inc., incorporated on December 10, 2008, is an endocrine-focused biopharmaceutical company. The Firm is engaged in developing long-acting recombinant human growth hormone (rhGH), somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Company’s product pipeline includes VRS-317 and XTEN Technology.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment